CLINICAL_TRIALS
trial_result
· 2023-11-07
Clinical Trial Update: Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1]
Summary
Phase 1 trial of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2023-11-07